Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059934 | 0.86 | FFAR1 (0.46) | RAB9AGAAMEN1KMT2A | |
| SCHEMBL5133548 | 0.85 | MAPT (0.39) | CCKBRRAB9ANPC1GAAMEN1 | |
| SCHEMBL5057825 | 0.84 | CYP3A4 (0.37) | USP2NPC1GAANLRP3TSHR | |
| SCHEMBL7050812 | 0.84 | AKR1C3 (0.45) | RAB9ANPC1CASRMEN1KMT2A | |
| SCHEMBL5052977 | 0.84 | GAA (0.41) | GAATSHRMEN1KMT2A | |
| SCHEMBL5057849 | 0.83 | FOLH1 (0.45) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL5054382 | 0.83 | ADRB2 (0.39) | RAB9ANPC1CASREGFRERBB3 | |
| SCHEMBL5054407 | 0.83 | FFAR1 (0.38) | NLRP3 | |
| SCHEMBL7047224 | 0.80 | FFAR1 (0.42) | RAB9AGAAMEN1KMT2A | |
| SCHEMBL5054477 | 0.80 | LMNA (0.41) | GAATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002509934-A | — | — | 2002-04-02 | — | — | JP | claimed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | claimed |
| US-6121252-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-09-19 | — | — | US | claimed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| EP-1066297-B1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6121252-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | MTNR1B 3550/4885MTNR1A 2939/4885USP2 536/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | MTNR1B 979/4885MTNR1A 932/4885USP2 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.